Literature DB >> 24642681

Targeted therapies: Imatinib prior to allogeneic HSCT therapy improves both relapse and nonrelapse survival in patients with Ph+ ALL.

David Killock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24642681     DOI： 10.1038/nrclinonc.2014.48

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL-positive acute lymphoblastic leukemia.

Authors:  Shuichi Mizuta; Keitaro Matsuo; Satoshi Nishiwaki; Kiyotoshi Imai; Heiwa Kanamori; Kazuteru Ohashi; Takahiro Fukuda; Yasushi Onishi; Koichi Miyamura; Satoshi Takahashi; Makoto Onizuka; Yoshiko Atsuta; Ritsuro Suzuki; Yasuo Morishima; Koji Kato; Hisashi Sakamaki; Junji Tanaka
Journal:  Blood       Date:  2014-03-03       Impact factor: 22.113
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.